Please use this identifier to cite or link to this item:
|Title:||Patients with abdominal aortic aneurysm: are we missing the opportunity for cardiovascular risk reduction?|
|Citation:||J VASC SURG, 2004, 40 (4), pp. 691-697|
|Abstract:||Antiplatelet agents, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statin drugs), angiotensin converting enzyme (ACE) inhibitors, and beta-adrenergic receptor blockers (beta-blockers) reduce cardiovascular risk and mortality in patients with specific manifestations of cardiovascular disease and risk factors. Occlusive arterial disease, in particular, coronary heart disease, is prevalent in patients with abdominal aortic aneurysm (AAA) and results in reduced life expectancy. The purpose of this study was to investigate the prevalence of cardiovascular disease and risk factors in patients with AAA. In particular, numbers of patients in whom pharmacologic therapy is indicated and numbers of patients who are receiving adequate treatment were determined.|
|Appears in Collections:||Published Articles, Dept. of Cardiovascular Sciences|
Files in This Item:
There are no files associated with this item.
Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.